TEW-7197 첫 용량 투여에서 안전성 확인, 용량증대 결정

Oct 21, 2015EVENTSHit 1800

On 14th of Oct. 2014 (13th in USA) SMC reviewed safety of the first cohort of TEW-7197 (NCT02160106) and did not find any drug-related toxicity. The committee recommended a dose escalation to the next level. Three clinical sites in the USA started recruitment of patients with solid tumor for the second cohort.

*About TEW-7197
TEW-7197, an inhibtor of ALK5 (TGF-beta receptor 1), is a small molecule for oral formulation. It blocks TGF-beta signaling efficiently and showed an excellent profile of safety and potency in non-clincal studies. It has a potential for the best-in-class oncology drug in its class. The development of TEW-7197 was supported by Program for Disease-based Discovery of Global New Durg Candidates and its clinical development is supported by National OncoVenture (NOV), National Cancer Center, Korea.

Next (주)메드팩토의 대주주이자 설립자인 김성진 박사가 공동대표자로 선임
Previous ANRT 와 협약